Home / Resource Library / An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma

An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma

Results of a phase II study of entospletinib for certain relapsed/refractory lymphomas.